Gene · 3568
Papers2,231
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 2,231
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Towards precision medicine in COPD: Targeting type 2 cytokines and alarmins. | Eur J Intern Med | 2024 | 38762432 | PubTator, text mining | PubMed |
| Identification of triciribine as a novel myeloid cell differentiation inducer. | PLoS One | 2024 | 38743735 | PubTator, text mining | PubMed |
| Whole blood transcriptomics reveals the enrichment of neutrophil activation pathways during erythema nodosum leprosum reaction. | Front Immunol | 2024 | 38715615 | PubTator, text mining | PubMed |
| The CC2D2B is a novel genetic modifier of the clinical phenotype in patients with hereditary angioedema due to C1 inhibitor deficiency. | Gene | 2024 | 38679185 | PubTator, text mining | PubMed |
| Flow cytometric immunophenotypic differentiation patterns of bone marrow eosinophilopoiesis. | Cytometry B Clin Cytom | 2024 | 38666394 | PubTator, text mining | PubMed |
| Severe Asthma or Chronic Obstructive Pulmonary Disease with Eosinophilic Inflammation? From Uncertainty to Remission under Anti IL-5R Therapy. | Medicina (Kaunas) | 2024 | 38541113 | PubTator, text mining | PubMed |
| Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study). | Pediatr Allergy Immunol | 2024 | 38491795 | PubTator, text mining | PubMed |
| Correction to "Long-term immune response accompanies clinical outcomes in severe asthmatics treated with anti-IL-5/IL-5R biologics". | Allergy | 2024 | 38470091 | PubTator, text mining | PubMed |
| The Effects of Benralizumab on Lung Volumes and Airway Resistance in Severe Eosinophilic Asthma: A Real-World Study. | Cureus | 2024 | 38371150 | PubTator, text mining | PubMed |
| Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial. | Br J Dermatol | 2024 | 38367194 | PubTator, text mining | PubMed |
| Improved small airway dysfunction in severe asthma with clinical remission by anti-interleukin-5/interleukin-5 receptor α. | Ann Allergy Asthma Immunol | 2024 | 38360105 | PubTator, text mining | PubMed |
| Causal relationship between inflammatory factors and cerebral small vessel disease: Univariate, multivariate, and summary-data-based mendelian randomization analysis. | Brain Behav | 2024 | 38340139 | PubTator, text mining | PubMed |
| Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission. | Front Immunol | 2024 | 38327518 | PubTator, text mining | PubMed |
| When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report. | J Med Case Rep | 2024 | 38291489 | PubTator, text mining | PubMed |
| Aseptic loosening around total joint replacement in humans is regulated by miR-1246 and miR-6089 via the Wnt signalling pathway. | J Orthop Surg Res | 2024 | 38287447 | PubTator, text mining | PubMed |
| Characteristics of mucin hypersecretion in different inflammatory patterns based on endotypes of chronic rhinosinusitis. | Clin Transl Allergy | 2024 | 38282195 | PubTator, text mining | PubMed |
| Novel Serum Biomarkers for Patients with Allergic Asthma Phenotype. | Biomedicines | 2024 | 38275403 | PubTator, text mining | PubMed |
| Exploring the risk of infection events in patients with asthma receiving anti-IL-5 monoclonal antibodies: A rapid systematic review and a meta-analysis. | Heliyon | 2024 | 38268596 | PubTator, text mining | PubMed |
| Benralizumab treatment in an elderly patient with eosinophilic esophagitis resulted in remission: a case report. | BMC Geriatr | 2024 | 38267847 | PubTator, text mining | PubMed |
| Anti-IL-5 and anti-IL-5R biologics for severe asthma. Are there any differences in their effects? | J Asthma | 2024 | 38266131 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3568/papers?page=11